Rosiglitazone and Exercise Training: Effects on HIV-Infected People With Insulin Resistance, Hypertriglyceridemia, and Adipose Tissue Maldistribution
HIV Infections, Insulin Resistance
About this trial
This is an interventional treatment trial for HIV Infections
Eligibility Criteria
The research volunteers will consist of HIV-infected men and women treated with PI-based HAART who have developed insulin resistance of impaired glucose homeostasis: fasting (8h) plasma glucose 110-126 mg/dL (6.1-7.1 mM) OR plasma glucose >140 (7.8 mM) 2 hours after a 75g-oral glucose load. Although not required for enrollment, many of these volunteers will also have developed trunk adipose tissue redistribution (defined as): trunk/appendicular adipose ratio using whole-body DEXA >1.1 (men), >0.9 (women), or visceral adipose/total abdominal adipose tissue (VAT/TAT) >0.40 using 1H-MRI imaging at the level of the umbilicus (~L3-L4 inter-vertebral space). Many will also have developed fasting hypertriglyceridemia (>300mg/dL, >3.4 mM). Plasma viremia (Roche Amplicor assay) <5000 copies/ml OR a CD4 T-cell county >= 200 cells/ul for at least 3 months prior to enrollment. Stable on a PI-containing HAART regimen for at least 3 months prior to enrollment. 18-65 years of age Body mass index <= 34kg/m*2, total body fat <=35% of weight
Sites / Locations
- Washington University School of Medicine